BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation.

Trial Profile

BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Mycophenolic acid
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Acronyms BeTACTIC
  • Most Recent Events

    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 04 May 2012 Actual initiation date (May 2010) added as reported by European Clinical Trials Database.
    • 23 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top